Consensus of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH) and the Brazilian Ministry of Health - General management of blood and blood products on the tests necessary for the release of exceptional medicines for sickle cell disease
Hematol., Transfus. Cell Ther. (Impr.)
; 46(1): 67-71, Jan.-Mar. 2024.
Article
en En
| LILACS
| ID: biblio-1557881
Biblioteca responsable:
BR408.1
Ubicación: BR408.1
ABSTRACT
Abstract To date, hydroxyurea is the only effective and safe drug that significantly reduces morbidity and mortality of individuals with Sickle cell disease. Twenty years of real-life experience has demonstrated that hydroxyurea reduces pain attacks, vaso-occlusive events, including acute chest syndrome, the number and duration of hospitalizations and the need for transfusion. The therapeutic success of hydroxyurea is directly linked to access to the drug, the dose used and adherence to treatment which, in part, is correlated to the availability of hydroxyurea. This consensus aims to reduce the number of mandatory exams needed to access the drug, prioritizing the requesting physician's report, without affecting patient safety.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Anemia de Células Falciformes
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Hematol., Transfus. Cell Ther. (Impr.)
Asunto de la revista:
Hematologia
/
TransfusÆo de Sangue
Año:
2024
Tipo del documento:
Article
País de afiliación:
Brasil
/
Estados Unidos
Pais de publicación:
Brasil